

Date: 14/12/2017

To,
Bombay Stock Exchange Limited,
Phiroz Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

Sub: - Unaudited Quarterly Financial Result under Regulation 33 of the of the SEBI (Listing Obligation And Disclosure Requirement) Regulation 2015, for the Quarter and half year ended 30th September, 2017
Company Scrip Code: 532167

Dear Sir,

Pursuant to the provisions of Regulation 33 of the of the SEBI (Listing Obligation And Disclosure Requirement) Regulation 2015, please find enclosed herewith, copy of the Unaudited Quarterly Financial Results of the Company, for the Quarter and half year ended 30th September, 2017, for your kind perusal and reference.

The aforesaid result has been approved by the Board of Directors at their meeting held on 14th December, 2017.

This is for your information and record.

Thanking You,

Yours faithfully,
For **Omkar Pharmachem Limited**



(Anurag Sharma)
Managing Director
DIN 02289261
Add: A-727, Sarita Vihar, New Delhi, 110076

Encl: a/a

Statement of Standalone Unaudited Financial Results for the Quarter and Six Months ended 30th September, 2017						
(Rs. in lacs except per share data)						
Sr. No.	Particulars	3 Months Ended 30-09-2017 (unaudited)	Preceding 3 months ended 30-06-2017 (unaudited)	Corresponding 3Months ended 30-09-2016 (unaudited)	6 Months Ended 30-09-2017 (unaudited)	Corosponding 6Months ended 30-09-2016 (unaudited)
Part-I						
1	Income from operations					
	a)Net Sales/ Income from Operations	0.00	0.00	0.00	0.00	0.00
	b)Other Operating Income	0.00	0.00	0.00	0	0
	Net Total income from Operations	0.00	0.00	0.00	0.00	0.00
2	Expenses					
	a) Cost of material consumed	0.00	0.00	0.00	0.00	0.00
	b) Purchase of Stock-in-trade	0.00	0.00	0.00	0.00	0.00
	c) Changes in Inventories of Finished Goods, WIP and Stock-in trade	0.00	0.00	0.00	0.00	0.00
	d) Employee benefits expenses	3.44	3.44	3.54	6.87	6.18
	f) Depreciation and Amortization Expenses	0.04	0.04	0.07	0.09	0.13
	g) Other Expenses	1.57	5.37	1.21	6.94	3.95
	Total Expenses	5.05	8.85	4.82	13.90	10.26
3	Profit(Loss) from operations before Other income, Finance cost, Exceptional Items & Taxes (1-2)	(5.05)	(8.85)	(4.82)	(13.90)	(10.26)
4	Other Income	0.00	0.00	0.18	0.00	0.43
5	Profit(Loss) before Finance cost, Exceptional Items & Taxes (3+4)	(5.05)	(8.85)	(4.64)	(13.90)	(9.83)
6	Finance Costs	0.01	0.04	0.00	0.05	0.00
7	Profit(Loss) from Ordinary Activities before Taxes and before exceptional items (5-6)	(5.06)	(8.89)	(4.64)	(13.95)	(9.83)
8	Exceptional items: Profit on sale of fixed assets	0.00	0.00	0.00	0.00	48.19
9	Profit(Loss) from Ordinary Activities before Tax(7-8)	(5.06)	(8.89)	(4.64)	(13.95)	38.36
10	Tax Expense	0.00	0.00	0.00	0.00	5.17
11	Profit(Loss) for the period (7+8)	(5.06)	(8.89)	(4.64)	(13.95)	33.19
12	Other Comprehensive Income (Expense)	0.00	0.00	0.00	0.00	0.00
13	Total Comprehensive Income for the period (9+10)	(5.06)	(8.89)	(4.64)	(13.95)	33.19
14	Paid up Equity Share Capital (Face Value Rs. 10/- each)	1008.37	1008.37	1008.37	1008.37	1008.37
14	Reserves excluding Revaluation Reserved as on 31st March	(70.65)	(70.65)	(92.71)	(70.65)	(92.71)
15	Earning Per Share(before & after extraordinary items)(of Rs. 10 each)(not annualised) Basic and diluted Rs.	(0.0502)	(0.0882)	(0.0460)	(0.1383)	0.3291



Statement of Assets and Liabilities		(Rs. In lacs)	
Sr. No	Particulars	As at 30-09-2017	As at 31-03-2017
		(Unaudited)	(Audited)
ASSETS			
Non-current Assets			
a)	Property, plant and equipment	0.23	0.32
b)	Capital work-in-progress	0.00	0.00
c)	Goodwill on consolidation	0.00	0.00
d)	Other intangible assets	0.00	0.00
e)	Intangible assets under development	0.00	0.00
f)	Financial assets	0.00	0.00
	i) Investments		
	a) Investment in associate	0.00	0.00
	b) Investments in joint ventures	0.00	0.00
	c) Other Investments	930.00	930.00
	ii) Other Financial Assets	0.00	0.00
g)	Deferred tax assets (net)	0.03	0.03
h)	Other non current assets	0.19	0.18
Total Non-current Assets		930.45	930.53
Current Assets			
a)	Inventories	0.00	0.00
b)	Financial assets		
	i) Other Investments	0.00	0.00
	ii) Trade receivables	7.46	7.46
	iii) Cash and cash equivalents	12.41	5.12
	iv) Bank balances other than iii) above	0.00	0.00
	v) Other financial assets	0	0
c)	Other current assets	0	0.00
Total Current Assets		19.87	12.58
Total Assets		950.32	943.11
EQUITY AND LIABILITIES			
Equity			
a)	Equity share capital	1008.37	1008.37
b)	Other equity : Reserve and Surplus	-84.60	-70.65
Equity attributable to the owners of the company		923.77	937.72
Non-controlling interests		0.00	0
Total Equity		923.77	937.72
Non-current liabilities			
Financial liabilities			
a)	Borrowings	0.00	0.00
b)	Provisions	0.00	0.00
c)	Deferred tax liabilities(Net)	0.00	0.00
Total Non-current Liabilities		0.00	0.00
Current Liabilities			
Financial liabilities			
	i) Borrowings	23.00	0.00
	ii) Trade Payables	1.80	3.15
	iii) Other financial liabilities	1.16	1.55
b)	Provisions	0.57	0.57
c)	Other current liabilities	0.02	0.12
Total-current Liabilities		26.55	5.39
Total Liabilities		26.55	5.39
Total Equity and Liabilities		950.32	943.11

Notes:

- The above results have been reviewed by the audit committee & approved by the Board of Directors at the respective meeting held on 14-12-2017
- Corresponding previous period figures are regrouped/rearranged wherever necessary, to make them comparable.
- The financial result for the Quarter and Half yearly ended on 30-09-2017 has been prepared in accordance with the IND-AS specified under section 133 of the companies Act and rules made thereunder.
- The IND-AS regarding segment reporting is not applicable to the company as there is no segment.
- Reserves includes reserves and surplus.
- There is no change in Net Profit /Loss of the company due to the transition from Indian GAAP to IND-AS. Hence Reconciliation statement is not required.

Date : 14-12-2017
Place: Ahmedabad

By order of the Board


Anurag Sharma

Managing Director

DIN-02289261

Add- A-727, Sarita Vihar

New Delhi-110076



Limited review report to The Board of Directors of Omkar Pharmachem Limited for quarter ended on 30th September, 2017

We have reviewed the accompanying statement of unaudited financial results of Omkar Pharmachem Limited for the quarter and half year ended on 30th September, 2017. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and; thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Ahmedabad
Date : 14/12/2017



For Rajesh J. Shah & Associates
Chartered Accountants
FRN 108407W


CA Jimit R. Shah)
Partner